The GLP-1 Briefing
From Body Compass
THE GLP-1 BRIEFING
Clear updates for a changing GLP-1 landscape.
New studies appear. Medications change. Regulatory decisions evolve. Oral treatments are emerging. Access can shift. Headlines can travel considerably faster than the evidence behind them.
The GLP-1 Briefing brings together the developments worth paying attention to and explains them in clear, patient-facing language.
You do not need to follow every announcement, trial or headline. Body Compass does that work so you can understand what changed, why it may matter and what remains uncertain.
Current information. Useful context. No unnecessary noise.
Not another stream of health headlines.
The GLP-1 Briefing is a regular Body Compass email for people who want to remain informed without spending their time searching through news reports, social media, research papers and competing claims.
Each edition focuses on developments that are genuinely worth understanding. That may include a significant trial result, a medication approval, an important safety communication, changes in treatment access, emerging evidence around maintenance or stopping treatment, or a new question entering the wider GLP-1 conversation.
Sometimes several things will matter. Sometimes very little will.
We will not manufacture news simply because an email is due.
The developments worth knowing about, placed in context.
The Briefing may include:
Important research
Significant trials, systematic reviews and evidence that may change how treatment is understood.
Medication developments
New formulations, indications, approvals and meaningful safety information.
Access and availability
Shortages, regulatory changes and other developments affecting access where relevant.
The changing landscape
Oral GLP-1 medications, combination therapies and emerging treatments.
Beyond starting treatment
Maintenance, changing response, stopping treatment, returning appetite and longer-term care.
Body Compass publications
New books, minibooks, resources and substantial programme developments.
Not every edition will contain every category. The content should follow the evidence, not a predetermined content calendar.
Monthly — with additional updates when something genuinely matters.
The GLP-1 Briefing is normally delivered once a month. Occasionally, an important development may justify an additional update — for example, a significant regulatory decision, safety communication or major change in the treatment landscape.
It is not intended to become a daily news service.
Enough to keep you informed. Not enough to become another source of noise.
Not every new study changes the story.
A single research paper can generate dozens of headlines. That does not necessarily mean clinical understanding has changed.
Before a development enters the GLP-1 Briefing, Body Compass asks:
- What actually happened?
- What is the original source?
- Is this established evidence, emerging evidence or preliminary information?
- Who was studied?
- How large was the finding?
- Does it change anything now?
- Is the information country-specific?
- What remains unknown?
- Does this development require action, discussion or simply awareness?
The goal is interpretation, not amplification.
No hype. No judgment. No promise that one answer fits everyone.
The GLP-1 Briefing will not use fear or exaggerated certainty to keep people opening emails. You should not expect:
- sensational “breaking news” subject lines for routine developments;
- miracle claims;
- scare stories built from isolated findings;
- automatic recommendations to switch medications;
- claims that one approach is right for everyone;
- shame about medication use, weight, hunger or treatment response;
- endless promotional emails disguised as education.
Body Compass publications, books, resources and services may occasionally be mentioned when they are genuinely relevant. They should never overwhelm the editorial purpose of the Briefing.
Keep up without having to keep searching.
Join The GLP-1 Briefing
Monthly evidence-informed updates on the GLP-1 landscape, in clear patient-facing language.
Delivered monthly, with additional updates when important developments occur. You can unsubscribe at any time.
By subscribing, you agree to receive The GLP-1 Briefing and occasional relevant Body Compass communications. Your information will be handled in accordance with the Body Compass Privacy Policy.
You’re on the list.
Thank you for joining The GLP-1 Briefing.
Check your inbox for confirmation and a short welcome from Body Compass.
Your first Briefing will arrive with the next scheduled edition, with additional updates only when an important development warrants one.
One confirmation. Then the Briefing.
Welcome email subject: Welcome to The GLP-1 Briefing
After subscribing, you will receive a short welcome email confirming your subscription and explaining what to expect. Your first Briefing will arrive with the next scheduled edition.
The welcome email will include links to Free Resources, Living on GLP-1 and Books & Minibooks as useful starting points while you wait.
Information changes. Dates matter.
GLP-1 medication approvals, indications, warnings, availability and prescribing guidance may differ between countries and can change. The GLP-1 Briefing will date time-sensitive information and identify important jurisdictional context where relevant.
Where an edition discusses a study, regulatory action or official guidance, readers should be able to follow the underlying source.
Body Compass will correct material factual errors when identified and substantially update articles or Briefings where the evidence changes.
Written with both the evidence and the person in view.
Already looking for something specific?
You do not need to wait for the next Briefing.
About The GLP-1 Briefing
The GLP-1 Briefing provides general educational information. It does not provide diagnosis, prescribing, medication adjustment, individualised medical advice or emergency care.
Medication indications, approvals, warnings, availability and clinical guidance may differ between countries and can change over time.
Individual symptoms, medications and treatment decisions should be discussed with appropriately qualified healthcare professionals.